Molecule of the month. Almorexant.
D000081:Acetamides / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D007546:Isoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D009479:Neuropeptides / Q000378:metabolism; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors; D018013:Receptors, Neuropeptide / Q000037:antagonists & inhibitors; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy* / Q000503:physiopathology
D000081:Acetamides; D047908:Intracellular Signaling Peptides and Proteins; D007546:Isoquinolines; D009479:Neuropeptides; D064446:Orexin Receptors; D000068797:Orexins; D043562:Receptors, G-Protein-Coupled; D018013:Receptors, Neuropeptide; C519150:almorexant